Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK

Drug and Alcohol Dependence

Volumn 126, Issue 3, 2012, Pages 324-332

  Mills, H L ^a   Colijn, C ^b   Vickerman, P ^c   Leslie, D ^a   Hope, V ^c,d   Hickman, M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Assortativity; HCV; Injecting drug users; Modelling; Network; Respondent driven sampling

Indexed keywords

ADULT; ARTICLE; COMMUNITY STRUCTURE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MODEL; MONITORING; MONTE CARLO METHOD; NETWORK MODEL; PREVALENCE; PRIORITY JOURNAL; SAMPLING; SIMULATION; UNITED KINGDOM;

ADULT; BIAS (EPIDEMIOLOGY); FEMALE; GREAT BRITAIN; HEPATITIS C; HUMANS; INCIDENCE; MALE; MONTE CARLO METHOD; PREVALENCE; SAMPLING STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

HEPATITIS C VIRUS;

EID: 84869219764     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.05.036     Document Type: Article

References (41)

1. Abdul-Quader A.S., Heckathorn D.D., McKnight C., Bramson H., Nemeth C., Sabin K., Gallagher K., Des Jarlais D.C. Effectiveness of respondent-driven sampling for recruiting drug users in New York City: findings from a pilot study. J. Urban Health 2006, 83:459-476.
2. Alter M., Moyer L. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 18(Suppl. 1):6-10.
3. Angelis D., Sweeting M., Ades A., Hickman M., Hope V., Ramsay M. An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales. Stat. Methods Med. Res. 2009, 18:361-379.
4. Boily M., Poulin R., Masse B. Some methodological issues in the study of sexual networks: from model to data to model. Sex. Transm. Dis. 2000, 27:558.
5. Crofts N., Jolley D., Kaldor J., van Beek I., Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J. Epidemiol. Community Health 1997, 51:692-697.
6. Des Jarlais D.C., Arasteh K., Perlis T., Hagan H., Abdul-Quader A., Heckathorn D.D., McKnight C., Bramson H., Nemeth C., Torian L.V., Friedman S.R. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007, 21:231.
7. EMCDDA, 2010. 2009 Annual Report on the State of the Drugs Problem in Europe. Lisbon.
8. Friedman S., Aral S. Social networks, risk-potential networks, health, and disease. J. Urban Health 2001, 78:411-418.
9. Friedman S., Curtis R., Neaigus A., Jose B., Des Jarlais D.C. Social Networks, Drug Injectors' Lives, and HIV/AIDS 1999, Kluwer/Plenum, New York.
10. Friedman S.R., Kottiri B.J., Neaigus A., Curtis R., Vermund S.H., Des Jarlais D.C. Network-related mechanisms may help explain long-term HIV-1 seroprevalence levels that remain high but do not approach population-group saturation. Am. J. Epidemiol. 2000, 152:913-922.
11. Ghani A., Donnelly C., Garnett G. Sampling biases and missing data in explorations of sexual partner networks for the spread of sexually transmitted diseases. Stat. Med. 1998, 17:2079-2097.
12. Gile K., Handcock M. Respondent-driven sampling: an assessment of current methodology. Soc. Method 2010, 40:285-327.
13. Goel S., Salganik M. Respondent-driven sampling as Markov chain Monte Carlo. Stats. Med. 2009, 28:2202-2229.
14. Goel S., Salganik M. Assessing respondent-driven sampling. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6743.
15. Hagan H., Des Jarlais D.C., Stern R., Lelutiu-Weinberger C., Scheinmann R., Strauss S., Flom P.L. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int. J. Drug Policy 2007, 18:341-351.
16. Harris R., Ramsay M., Hope V.D., Brant L., Hickman M., Foster G.R., De Angelis D. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur. J. Public Health 2011, 22:187-192.
17. Heckathorn D. Respondent-driven sampling: a new approach to the study of hidden populations. Soc. Probl. 1997, 44:174-199.
18. Heckathorn D. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc. Probl. 2002, 49:11-34.
19. Heckathorn D., Rosenstein J. Group solidarity as the product of collective action: creation of solidarity in a population of injection drug users. Advances in Group Processes 2002, 37-66. Emerald Group Publishing Limited, United Kingdom. S.R. Thye, E. Lawler (Eds.).
20. Heckathorn D., Semaan S., Broadhead R., Hughes J. Extensions of respondent-driven sampling: a new approach to the study of injection drug users aged 18-25. AIDS Behav. 2002, 6:55-67.
21. Heimer R. Critical issues and further questions about respondent-driven sampling: comment on Ramirez-Valles et al., 2005. AIDS Behav. 2005, 9:403-408.
22. Hickman M., Hope V., Brady T., Madden P., Jones S., Honor S., Holloway G., Ncube F., Parry J. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J. Viral Hepat. 2007, 14:645-652.
23. Hickman M., Hope V., Coleman B., Parry J., Telfer M., Twigger J., Irish C., Macleod J., Annett H. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J. Public Health 2009, 31:374-382.
24. Hope V.D., Hickman M., Ngui S.L., Jones S., Telfer M., Bizzarri M., Ncube F., Parry J.V. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J. Viral Hepat. 2011, 18:262-270.
25. Johnston L., Malekinejad M., Rifkin M.R., Rutherford G.W., Kendall C. Implementation challenges to using respondent-driven sampling methodology for HIV biological and behavioral surveillance: field experiences in international settings. AIDS Behav. 2008, 12:131-141.
26. Kral A.H., Malekinejad M., Vaudrey J., Martinez A.N., Lorvick J., McFarland W., Raymond H.F. Comparing respondent-driven sampling and targeted sampling methods of recruiting injection drug users in San Francisco. J. Urban Health 2010, 87:839-850.
27. Malekinejad M., Johnston L.G., Kendall C., Kerr L.R.F.S., Rifkin M.R., Rutherford G.W. Using respondent-driven sampling methodology for HIV biological and behavioral surveillance in international settings: a systematic review. AIDS Behav. 2008, 12:105-130.
28. McCreesh N., Frost S.D., Seeley J., Katongole J., Tarsh M.N., Ndunguse R., Jichi F., Lunel N.L., Maher D., Johnston L.G., Sonnenberg P., Copas A.J., Hayes R.J., White R.G. Evaluation of respondent-driven sampling. Epidemiology 2012, 23:138-147.
29. Neaigus A., Friedman S.R., Goldstein M., Ildefonso G., Curtis R., Jose B. Using dyadic data for a network analysis of HIV infection and risk behaviors among injecting drug users. NIDA Res. Monogr. 1995, 151:20-37.
30. Newman M. Mixing patterns in networks. Phys. Rev. E 2003, 67:026126.
31. Paquette D., Bryant J., Wit J.D. Respondent-driven sampling and the recruitment of people with small injecting networks. AIDS Behav. 2011, 16:890-899.
32. Paquette D., Bryant J., Wit J.D. Use of respondent-driven sampling to enhance understanding of injecting networks: a study of people who inject drugs in Sydney, Australia. Int. J. Drug Policy 2011, 22:267-273.
33. Robinson W.T., Risser J.M., McGoy S., Becker A.B., Rehman H., Jefferson M., Griffin V., Wolverton M., Tortu S. Recruiting injection drug users: a three-site comparison of results and experiences with respondent-driven and targeted sampling procedures. J. Urban Health 2006, 83:29-38.
34. Salathe M., Jones J. Dynamics and control of diseases in networks with community structure. PLoS Comput. Biol. 2010, 6:e1000736.
35. Salathe M., Khandelwal S. Assessing vaccination sentiments with online social media: implications for infectious disease dynamics and control. PLoS Comput. Biol. 2011, 7:e1002199.
36. Salganik M. Commentary: respondent-driven sampling in the real world. Epidemiology 2012, 23:148-150.
37. Shepard C., Finelli L., Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
38. Turner K.M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., May M., Taylor A., De Angelis D., Cameron S., Parry J., Lyons M., Goldberg D., Allen E., Hickman M. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011, 106:1978-1988.
39. Vickerman P., Hickman M., Judd A. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. Int. J. Epidemiol. 2007, 36:396-405.
40. Volz E., Heckathorn D. Probability based estimation theory for respondent driven sampling. J. Off. Stat. 2008, 24:79-97.
41. Volz E., Wejnert C., Degani I., Heckathorn D. Respondent-Driven Sampling Analysis Tool (RDSAT), Version 5.6 2007, Cornell University, Ithaca.